Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.

Fritsche-Guenther R, Zasada C, Mastrobuoni G, Royla N, Rainer R, Roßner F, Pietzke M, Klipp E, Sers C, Kempa S.

Sci Rep. 2018 Jun 15;8(1):9204. doi: 10.1038/s41598-018-27394-1.

2.

Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids.

Riemer P, Rydenfelt M, Marks M, van Eunen K, Thedieck K, Herrmann BG, Blüthgen N, Sers C, Morkel M.

J Cell Biol. 2017 Jun 5;216(6):1567-1577. doi: 10.1083/jcb.201610058. Epub 2017 Apr 25.

3.

Robust in-silico identification of cancer cell lines based on next generation sequencing.

Otto R, Sers C, Leser U.

Oncotarget. 2017 May 23;8(21):34310-34320. doi: 10.18632/oncotarget.16110.

4.

DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C.

Nat Commun. 2017 Jan 25;8:14093. doi: 10.1038/ncomms14093.

5.

Unraveling the regulation of mTORC2 using logical modeling.

Thobe K, Sers C, Siebert H.

Cell Commun Signal. 2017 Jan 19;15(1):6. doi: 10.1186/s12964-016-0159-5.

6.

WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine.

Pavel ME, Sers C.

Endocr Relat Cancer. 2016 Nov;23(11):T135-T154. Epub 2016 Sep 20. Review.

7.

Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling.

Möller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, Riemer P, Schmid S, Schmitt LC, Kontermann R, Mürdter T, Schwab M, Sers C, Olayioye MA.

Oncotarget. 2016 Aug 16;7(33):53526-53539. doi: 10.18632/oncotarget.10658.

8.

SoFIA: a data integration framework for annotating high-throughput datasets.

Childs LH, Mamlouk S, Brandt J, Sers C, Leser U.

Bioinformatics. 2016 Sep 1;32(17):2590-7. doi: 10.1093/bioinformatics/btw302. Epub 2016 May 13.

PMID:
27187206
9.

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.

Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N.

Oncotarget. 2016 Feb 16;7(7):7960-9. doi: 10.18632/oncotarget.6959.

10.

Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer.

Roßner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, Dietel M, Schäfer R, Sers C.

Oncogenesis. 2016 Jan 18;5:e187. doi: 10.1038/oncsis.2015.51.

11.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.

Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review.

PMID:
26358176
12.
13.

Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer.

Jesinghaus M, Wolf T, Pfarr N, Muckenhuber A, Ahadova A, Warth A, Goeppert B, Sers C, Kloor M, Endris V, Stenzinger A, Weichert W.

Am J Surg Pathol. 2015 Aug;39(8):1140-7. doi: 10.1097/PAS.0000000000000423.

PMID:
25786087
14.

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M.

Lung Cancer. 2015 Feb;87(2):122-9. doi: 10.1016/j.lungcan.2014.11.018. Epub 2014 Dec 6.

PMID:
25534130
15.

Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.

Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M.

Oncogene. 2015 Jun 11;34(24):3164-75. doi: 10.1038/onc.2014.247. Epub 2014 Aug 11.

PMID:
25109331
16.

Ras-mediated deregulation of the circadian clock in cancer.

Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, Riemer P, Mang-Fatehi S, Maier B, Schäfer R, Leser U, Herzel H, Kramer A, Sers C.

PLoS Genet. 2014 May 29;10(5):e1004338. doi: 10.1371/journal.pgen.1004338. eCollection 2014.

17.

Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology.

Gries J, Schumacher D, Arand J, Lutsik P, Markelova MR, Fichtner I, Walter J, Sers C, Tierling S.

Epigenetics. 2013 Jul;8(7):765-71. doi: 10.4161/epi.25242. Epub 2013 Jun 10.

18.

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N.

Mol Syst Biol. 2013;9:673. doi: 10.1038/msb.2013.29.

19.

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert M, Hummel M, Bläker H, Müller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I.

Cancer Gene Ther. 2013 Apr;20(4):211-21. doi: 10.1038/cgt.2013.13. Epub 2013 Mar 15. Review.

PMID:
23492822
20.

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R.

Mol Syst Biol. 2012;8:601. doi: 10.1038/msb.2012.32.

21.

An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity.

Kuehnen P, Mischke M, Wiegand S, Sers C, Horsthemke B, Lau S, Keil T, Lee YA, Grueters A, Krude H.

PLoS Genet. 2012;8(3):e1002543. doi: 10.1371/journal.pgen.1002543. Epub 2012 Mar 15.

22.

Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Warth A, Penzel R, Brandt R, Sers C, Fischer JR, Thomas M, Herth FJ, Dietel M, Schirmacher P, Bläker H.

Virchows Arch. 2012 Apr;460(4):407-14. doi: 10.1007/s00428-012-1219-x. Epub 2012 Mar 15.

PMID:
22419261
23.

MsLDR-creator: a web service to design msLDR assays.

Bormann F, Dahl A, Sers C.

Mol Genet Genomics. 2012 Mar;287(3):273-4. doi: 10.1007/s00438-012-0677-9. Epub 2012 Jan 26.

PMID:
22278756
24.

Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns.

Bormann F, Sers C, Seliger B, Handke D, Bergmann T, Seibt S, Lehrach H, Dahl A.

Mol Genet Genomics. 2011 Oct;286(3-4):279-91. doi: 10.1007/s00438-011-0645-9. Epub 2011 Aug 31.

PMID:
21879293
25.

Strong negative feedback from Erk to Raf confers robustness to MAPK signalling.

Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Blüthgen N.

Mol Syst Biol. 2011 May 24;7:489. doi: 10.1038/msb.2011.27.

26.

A fast, cost-efficient and sensitive approach for KRAS mutation detection using multiplexed primer extension with IP/RP-HPLC separation.

Tierling S, Sers C, Lehmann A, Walter J.

Int J Cancer. 2012 Feb 1;130(3):567-74. doi: 10.1002/ijc.26040. Epub 2011 Apr 27.

27.

A helminth immunomodulator exploits host signaling events to regulate cytokine production in macrophages.

Klotz C, Ziegler T, Figueiredo AS, Rausch S, Hepworth MR, Obsivac N, Sers C, Lang R, Hammerstein P, Lucius R, Hartmann S.

PLoS Pathog. 2011 Jan 6;7(1):e1001248. doi: 10.1371/journal.ppat.1001248.

28.
29.

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.

Jürchott K, Kuban RJ, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kiełbasa SM, Ungethüm U, Lund P, Knösel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schäfer R.

PLoS Genet. 2010 Dec 2;6(12):e1001231. doi: 10.1371/journal.pgen.1001231.

30.

Therapeutic potential of CAMPATH-1H in skeletal tumours.

Fritsche-Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser KD, Schlag PM, Kasper HU, Krenn V, Sers C.

Histopathology. 2010 Dec;57(6):851-61. doi: 10.1111/j.1365-2559.2010.03722.x.

PMID:
21166699
31.

De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway.

Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, Karle J, Krenn V, Dietel M, Sers C.

Histopathology. 2010 Dec;57(6):836-50. doi: 10.1111/j.1365-2559.2010.03713.x.

PMID:
21166698
32.

RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function.

Schäfer R, Sers C.

Adv Enzyme Regul. 2011;51(1):126-36. doi: 10.1016/j.advenzreg.2010.11.005. Epub 2010 Nov 20. Review.

PMID:
21094659
33.

EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.

Penzel R, Sers C, Chen Y, Lehmann-Mühlenhoff U, Merkelbach-Bruse S, Jung A, Kirchner T, Büttner R, Kreipe HH, Petersen I, Dietel M, Schirmacher P.

Virchows Arch. 2011 Jan;458(1):95-8. doi: 10.1007/s00428-010-1000-y. Epub 2010 Nov 6.

PMID:
21057810
34.

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

Kasajima A, Sers C, Sasano H, Jöhrens K, Stenzinger A, Noske A, Buckendahl AC, Darb-Esfahani S, Müller BM, Budczies J, Lehman A, Dietel M, Denkert C, Weichert W.

Hum Pathol. 2010 Dec;41(12):1758-69. doi: 10.1016/j.humpath.2010.05.014.

PMID:
20869097
35.

Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.

Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, Sehouli J, Legewie S, Herbst L, Weichert W, Darb-Esfahani S, Dietel M, Schäfer R, Ueberall F, Sers C.

Mol Cancer Res. 2010 Jun;8(6):919-34. doi: 10.1158/1541-7786.MCR-09-0358. Epub 2010 May 25.

36.

Systems biologists seek fuller integration of systems biology approaches in new cancer research programs.

Wolkenhauer O, Auffray C, Baltrusch S, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JE Jr, Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, Jaster R.

Cancer Res. 2010 Jan 1;70(1):12-3. doi: 10.1158/0008-5472.CAN-09-2676. Epub 2009 Dec 22.

37.

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M.

J Mol Diagn. 2010 Jan;12(1):35-42. doi: 10.2353/jmoldx.2010.090079. Epub 2009 Dec 10.

38.

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer U, Poustka A, Schäfer R.

Int J Cancer. 2009 Oct 1;125(7):1626-39. doi: 10.1002/ijc.24557.

39.

Modelling and simulating interleukin-10 production and regulation by macrophages after stimulation with an immunomodulator of parasitic nematodes.

Figueiredo AS, Höfer T, Klotz C, Sers C, Hartmann S, Lucius R, Hammerstein P.

FEBS J. 2009 Jul;276(13):3454-69. doi: 10.1111/j.1742-4658.2009.07068.x. Epub 2009 May 18.

40.

A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts.

Blüthgen N, Legewie S, Kielbasa SM, Schramme A, Tchernitsa O, Keil J, Solf A, Vingron M, Schäfer R, Herzel H, Sers C.

FEBS J. 2009 Feb;276(4):1024-35. doi: 10.1111/j.1742-4658.2008.06846.x. Epub 2009 Jan 12.

41.

Kinetic mechanisms for overexpression insensitivity and oncogene cooperation.

Legewie S, Sers C, Herzel H.

FEBS Lett. 2009 Jan 5;583(1):93-6. doi: 10.1016/j.febslet.2008.11.027. Epub 2008 Dec 4.

42.

HMGA2 gene is a promising target for ovarian cancer silencing therapy.

Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O.

Int J Cancer. 2008 Jul 15;123(2):348-356. doi: 10.1002/ijc.23491.

43.

Oncogenic signaling pathways and deregulated target genes.

Schäfer R, Schramme A, Tchernitsa OI, Sers C.

Recent Results Cancer Res. 2007;176:7-24. Review.

PMID:
17607912
44.

Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells.

Nazarenko I, Schäfer R, Sers C.

J Cell Sci. 2007 Apr 15;120(Pt 8):1393-404. Epub 2007 Mar 20.

45.

Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.

Schäfer R, Tchernitsa OI, Györffy B, Serra V, Abdul-Ghani R, Lund P, Sers C.

Adv Enzyme Regul. 2007;47:41-62. Epub 2007 Mar 1. Review. No abstract available.

PMID:
17335873
46.

Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer.

Chen Y, Pacyna-Gengelbach M, Ye F, Knösel T, Lund P, Deutschmann N, Schlüns K, Kotb WF, Sers C, Yasumoto H, Usui T, Petersen I.

J Pathol. 2007 Mar;211(4):431-8.

PMID:
17236181
47.

H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling.

Nazarenko I, Kristiansen G, Fonfara S, Guenther R, Gieseler C, Kemmner W, Schafer R, Petersen I, Sers C.

Am J Pathol. 2006 Oct;169(4):1427-39.

48.

Effects of Ras signaling on gene expression analyzed by customized microarrays.

Tchernitsa OI, Sers C, Geflitter A, Schäfer R.

Methods Enzymol. 2006;407:373-87.

PMID:
16757339
49.

Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Dietel M, Sers C.

Virchows Arch. 2006 Jun;448(6):744-55. Epub 2006 Apr 22. Review.

PMID:
16736190
50.

Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.

Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, Schaefer B, Sehouli J, Dietel M, Lage H, Denkert C.

Cancer Lett. 2007 Feb 8;246(1-2):190-200. Epub 2006 Apr 3.

PMID:
16584837

Supplemental Content

Support Center